American Health Intel Rules. Money. Medicine. Decoded daily.
Subscribe
← All editions
Following a story · 2 updates

DEA schedules oveporexton in Schedule IV

Aug 6, 2026 – Nov 13, 2026

  1. Aug 6, 2026 The Regulator Approval

    FDA approves first drug treating narcolepsy type 1 at its root cause

    The FDA approved Takeda's Orzeyful (oveporexton) on August 5, 2026 as an oral orexin receptor 2 agonist that restores signaling lost in narcolepsy type 1, though the DEA's controlled substance scheduling decision, expected within 90 days, must come before patients can access it through specialty pharmacy.

    Read this issue →
  2. Nov 13, 2026 The Regulator Rule Latest

    DEA schedules oveporexton in Schedule IV

    DEA issued an interim final rule placing Takeda's narcolepsy drug oveporexton (Orzeyful) in Schedule IV, effective November 12, with comments and hearing requests due December 14.

    Read this issue →